ReviewBritish journal of pharmacology2012
Retinoids: novel immunomodulators and tumour-suppressive agents?
Review in British journal of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Vitamin A and its influence on tumour extracellular matrix.Discover oncology · 2025Review
- Fat-soluble Vitamins and Lung Cancer: Where We Are?Recent patents on anti-cancer drug discovery · 2025Review
- Pet Wellness and Vitamin A: A Narrative Overview.Animals : an open access journal from MDPI · 2024Review
- Retinoids in Fungal Infections: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Review
- Trifarotene: A Current Review and Perspectives in Dermatology.Biomedicines · 2021Review
- Diet as a Potential Moderator for Genome Stability and Immune Response in Pediatric Leukemia.Cancers · 2021Review
- Revealing the Potential Application of EC-Synthetic Retinoid Analogues in Anticancer Therapy.Molecules (Basel, Switzerland) · 2021Article
- Second Primary Malignancy after Acute Promyelocytic Leukemia: A Population-Based Study.Cancers · 2020Article
- The immunomodulatory potential of natural compounds in tumor-bearing mice and humans.Critical reviews in food science and nutrition · 2019Review
- Immune cells in the tumour: new routes of retinoids for chemoprevention and chemotherapeutics.British journal of pharmacology · 2018Review
- All-Trans Retinoic Acid Modulates TLR4/NF-Mediators of inflammation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoids play important roles in the transcriptional activity of normal, degenerative and tumour cells. Retinoid analogues may be promising therapeutic agents for the treatment of immune disorders as different as type I diabetes and systemic lupus erythematosus. In addition, the use of retinoids in cancer treatment has progressed significantly in the last two decades; thus, numerous retinoid compounds have been synthesized and tested. In this paper, the actual or potential use of retinoids as immunomodulators or tumour-suppressive agents is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.